Thrombin Receptors (Thrombin Receptor)

A family of proteinase-activated receptors that are specific for THROMBIN. They are found primarily on PLATELETS and on ENDOTHELIAL CELLS. Activation of thrombin receptors occurs through the proteolytic action of THROMBIN, which cleaves the N-terminal peptide from the receptor to reveal a new N-terminal peptide that is a cryptic ligand for the receptor. The receptors signal through HETEROTRIMERIC GTP-BINDING PROTEINS. Small synthetic peptides that contain the unmasked N-terminal peptide sequence can also activate the receptor in the absence of proteolytic activity.

Also Known As:

Networked: 338 relevant articles (9 outcomes, 87 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Mahaffey, Kenneth W: 20 articles (01/2022 - 01/2012)
2.	Tricoci, Pierluigi: 20 articles (01/2020 - 10/2010)
3.	White, Harvey D: 20 articles (01/2020 - 01/2012)
4.	Harrington, Robert A: 19 articles (01/2020 - 01/2012)
5.	Wallentin, Lars: 18 articles (01/2022 - 01/2012)
6.	Armstrong, Paul W: 18 articles (01/2020 - 01/2012)
7.	Moliterno, David J: 17 articles (12/2018 - 01/2012)
8.	Van de Werf, Frans: 17 articles (12/2018 - 11/2010)
9.	Held, Claes: 16 articles (12/2018 - 01/2012)
10.	Aylward, Philip E: 16 articles (01/2018 - 01/2012)

Related Diseases

1.	Acute Coronary Syndrome 09/01/2009 - "The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale." 07/03/2012 - "The thrombin receptor, PAR1, has recently emerged as a promising new target for therapeutic intervention in patients with acute coronary syndromes. " 01/01/2018 - "Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial." 03/14/2017 - "In 12 944 patients with non-ST-segment elevation ACS from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial, we investigated the relative impact of MI and bleeding occurring >30 days post-ACS and subsequent all-cause mortality. " 05/01/2015 - "Meta-analysis for the efficacy and safety data of thrombin-receptor antagonist (TRA) based on patients with acute coronary syndrome (ACS) or coronary artery disease (CAD) and indirect comparisons between TRAs were not available. "
2.	Hemorrhage 02/01/2008 - "Early data from a clinical trial (TRA-PCI) to evaluate safety and efficacy of a potent new oral thrombin receptor antagonist (TRA) have promisingly indicated that overall TRA treatment reduces adverse event rates without an increase in bleeding risk. " 02/01/1998 - "Seventy-nine patients were entered into a study designed to measure changes in platelet thrombin receptor function during CPB and to correlate them to postoperative bleeding. " 07/01/2022 - "The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population." 03/01/2018 - "Perinatal lethality of Par4-/- mice delivered by primiparous dams reveals spontaneous bleeding in mice without platelet thrombin receptor function." 02/01/1998 - "The platelet thrombin receptor and postoperative bleeding."
3.	Thrombosis (Thrombus) 07/01/1999 - "An antagonist specific for the thrombin receptor is expected to be a remedy for thrombosis. " 08/02/2013 - "Targeting platelet thrombin receptor signaling to prevent thrombosis." 01/01/2010 - "Platelet thrombin receptor antagonism and atherothrombosis." 06/10/1997 - "[Thrombin receptor in thrombosis]." 06/15/1995 - "The effect of thrombin receptor blockade by this antibody on arterial thrombosis was evaluated in an in vivo model of platelet-dependent cyclic flow reductions (CFRs) in the carotid artery of the AGM. "
4.	Neoplasm Metastasis (Metastasis) 01/01/2011 - "The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target." 12/01/2001 - "Therefore, the use of antiplatelet agents especially via thrombin receptors may help to prevent TCIPA or metastasis by CCA." 01/01/2014 - "Genetic deletion of the thrombin receptor PAR1 or endothelial thrombin signaling targets alone did not diminish enhanced metastasis in TM(Pro) mice. " 04/06/2001 - "The first prototype of the protease activated receptor (PAR) family, the thrombin receptor PAR1, plays a central role both in the malignant invasion process of breast carcinoma metastasis and in the physiological process of placental implantation. " 04/29/2010 - "Thorough preclinical investigations have, at least in part, clarified some specifics regarding the involvement of platelet adhesion receptors, such as thrombin receptors or integrins, in the metastasis cascade. "
5.	Cardiovascular Diseases (Cardiovascular Disease) 03/01/1994 - "Thrombin receptor function and cardiovascular disease." 01/01/2022 - "There is growing evidence of the importance of protease-activated receptor 4 (PAR4), one of thrombin receptors, as a therapeutic target in thrombotic cardiovascular diseases. " 01/01/2017 - "Strikingly, these features relate to numerous genes with a key role in the pathogenesis of cardiovascular disease, especially thrombin signaling, including the thrombin receptors on platelets F2R (coagulation factor II (thrombin) receptor; PAR1) and GP5 (glycoprotein 5), as well as HMOX1 (haem oxygenase 1) and BCL2L1 (BCL2-like 1) which are involved in protection against oxidative stress and apoptosis, respectively. "

Related Drugs and Biologics

1.	vorapaxar
2.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
3.	Thrombin Receptors (Thrombin Receptor)
4.	Thrombin
5.	Prothrombin (Factor II)
6.	Glycoproteins (Glycoprotein)
7.	Prasugrel Hydrochloride
8.	Collagen
9.	von Willebrand Factor
10.	Purinergic P2Y Receptor Antagonists

Related Therapies and Procedures

1.	Therapeutics
2.	Secondary Prevention
3.	Lasers (Laser)
4.	Percutaneous Coronary Intervention
5.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)